Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors

Journal of Medicinal Chemistry

Volumn 54, Issue 24, 2011, Pages 8271-8277

  Touisni, Nadia ^a   Maresca, Alfonso ^b   McDonald, Paul C ^c   Lou, Yuanmei ^c   Scozzafava, Andrea ^d   Dedhar, Shoukat ^c,d   Winum, Jean Yves ^a   Supuran, Claudiu T ^b  

^a INSTITUT CHARLES GERHARDT   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLUMBELLIFER 7 YL ALPHA DEXTRO MANNOPYRANOSIDE; 4 METHYLUMBELLIFER 7 YL ALPHA LEVO RHAMNOPYRANOSIDE; 4 METHYLUMBELLIFER 7 YL BETA DEXTRO GALACTOPYRANOSIDE; 4 METHYLUMBELLIFER 7 YL BETA DEXTRO GLUCOPYRANOSIDE; 4 METHYLUMBELLIFER 7 YL BETA DEXTRO MELIBIOPYRANOSIDE; 4 METHYLUMBELLIFER 7 YL BETA DEXTRO RIBOPYRANOSIDE; 4 METHYLUMBELLIFER 7 YL BETA DEXTRO XYLOPYRANOSIDE; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE I; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; COUMARIN DERIVATIVE; UMBELLIFERONE C; UMBELLIFERONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIMARY TUMOR; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CELL HYPOXIA; COUMARINS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84055176334     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200983e     Document Type: Article

References (47)

1. Maresca, A.; Temperini, C.; Vu, H.; Pham, N. B.; Poulsen, S. A.; Scozzafava, A.; Quinn, R. J.; Supuran, C. T. Non-zinc mediated inhibition of carbonic anhydrases: Coumarins are a new class of suicide inhibitors. J. Am. Chem. Soc. 2009, 131, 3057-3062.
2. Maresca, A.; Temperini, C.; Pochet, L.; Masereel, B.; Scozzafava, A.; Supuran, C. T. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J. Med. Chem. 2010, 53, 335-344.
3. (a) Neri, D.; Supuran, C. T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discovery 2011, 10, 767-777.
4. (b) Supuran, C. T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discovery 2008, 7, 168-181.
5. (c) Supuran, C. T.; Scozzafava, A.; Casini, A. Development of sulfonamide carbonic anhydrase inhibitors (CAIs). In Carbonic anhydrase: Its Inhibitors and Activators; Supuran, C. T., Scozzafava, A., and Conway, J., Eds.; CRC Press: Boca Raton, FL, 2004; pp 67-147.
6. (a) Švastová, E.; Hulíková, A.; Rafajová, M.; Zat'ovičová, M.; Gibadulinová, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C.; Pastorek, J. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577, 439-445.
7. (b) Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev. 2003, 23, 146.
8. (c) Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 2004, 19, 199-229.
9. (d) Thiry, A.; Dogné, J.-M.; Masereel, B.; Supuran, C. T. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci. 2006, 27, 566-573.
10. (a) Ebbesen, P.; Pettersen, E. O.; Gorr, T. A.; Jobst, G.; Williams, K.; Kienninger, J.; Wenger, R. H.; Pastorekova, S.; Dubois, L.; Lambin, P.; Wouters, B. G.; Supuran, C. T.; Poellinger, L.; Ratcliffe, P.; Kanopka, A.; Görlach, A.; Gasmann, M.; Harris, A. L.; Maxwell, P.; Scozzafava, A. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J. Enzyme Inhib. Med. Chem. 2009, 24 (S1), 1-39.
11. (b) Dubois, L.; Lieuwes, N. G.; Maresca, A.; Thiry, A.; Supuran, C. T.; Scozzafava, A.; Wouters, B. G.; Lambin, P. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother. Oncol. 2009, 92, 423-428.
12. (c) Ahlskog, J. K. J.; Dumelin, C. E.; Trussel, S.; Marlind, J.; Neri, D. Bioorg. Med. Chem. Lett. 2009, 19, 4851.
13. (d) Ahlskog, J. K.; Schliemann, C.; Mårlind, J.; Qureshi, U.; Ammar, A.; Pedleym, R. B.; Neri, D. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg. Med. Chem. Lett. 2009, 19, 4851-4856.
14. (e) Buller, F.; Steiner, M.; Frey, K.; Mircsof, D.; Scheuermann, J.; Kalisch, M.; Bühlmann, P.; Supuran, C. T.; Neri, D. Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds. ACS Chem. Biol. 2011, 6, 336-344.
15. Carta, F.; Temperini, C.; Innocenti, A.; Scozzafava, A.; Kaila, K.; Supuran, C. T. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J. Med. Chem. 2010, 53, 5511-5522.
16. (a) Alterio, V.; Di Fiore, A.; D'Ambrosio, K.; Supuran, C. T.; De Simone, G. X-ray crystallography of CA inhibitors and its importance in drug design. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications; Supuran, C. T., Winum, J. Y., Eds.; Wiley: Hoboken, NJ, 2009; pp 73-138.
17. (b) Alterio, V.; Hilvo, M.; Di Fiore, A.; Supuran, C. T.; Pan, P.; Parkkila, S.; Scaloni, A.; Pastorek, J.; Pastorekova, S.; Pedone, C.; Scozzafava, A.; Monti, S. M.; De Simone, G. Crystal structure of the extracellular catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 16233-16238.
18. Innocenti, A.; Durdagi, S.; Doostdar, N.; Strom, T. A.; Barron, A. R.; Supuran, C. T. Nanoscale enzyme inhibitors: Fullerenes inhibit carbonic anhydrase by occluding the active site entrance. Bioorg. Med. Chem. 2010, 18, 2822-2828.
19. (a) Maresca, A.; Supuran, C. T. Coumarins incorporating hydroxy- and chloro- moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. Bioorg. Med. Chem. Lett. 2010, 20, 4511-4514.
20. (b) Maresca, A.; Scozzafava, A.; Supuran, C. T. 7,8-Disubstituted but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg. Med. Chem. Lett. 2010, 20, 7255-7258.
21. (a) Supuran, C. T. Carbonic anhydrase inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 3467-3474.
22. (b) Supuran, C. T. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med. Chem. 2011, 3, 1165-1180.
23. (a) Supuran, C. T. Indisulam: An anticancer sulfonamide in clinical development. Expert Opin. Invest. Drugs 2003, 12, 283-287.
24. (b) Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastoreková, S.; Scozzafava, A.; Winum, J.-Y.; Montero, J.-L.; Supuran, C. T. Carbonic anhydrase inhibitors. Sulfonamides inhibit isozyme IX mediated acidification of hypoxic tumors. Fluorescent sulfonamides design as probes of membrane-bound carbonic anhydrase isozymes involvement in tumorigenesis. J. Med. Chem. 2005, 48, 4834-4841.
25. 2 diffusion. BJU Int. 2008, 101 (Suppl. 4), 22-24.
26. (d) Mincione, F.; Scozzafava, A.; Supuran, C. T. Antiglaucoma carbonic anhydrase inhibitors as ophthalomologic drugs. In Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications; Supuran, C. T., Winum, J. Y., Eds.; Wiley: Hoboken, NJ, 2009; pp 139-154.
27. (a) Kivelä, A. J.; Parkkila, S.; Saarnio, J.; Karttunen, T. J.; Kivelä, J.; Parkkila, A. K.; Pastoreková, S.; Pastorek, J.; Waheed, A.; Sly, W. S.; Rajaniemi, H. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. Histochem. Cell Biol. 2000, 114, 197-204.
28. (b) Swietach, P.; Wigfield, S.; Cobden, P.; Supuran, C. T.; Harris, A. L.; Vaughan-Jones, R. D. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growth. J. Biol. Chem. 2008, 283, 20473-20483.
29. Supuran, C. T. Carbonic anhydrases as drug targets. Curr. Pharm. Des. 2008, 14, 601-602.
30. Pacchiano, F.; Carta, F.; McDonald, P. C.; Lou, Y.; Vullo, D.; Scozzafava, A.; Dedhar, S.; Supuran, C. T. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. Med. Chem. 2011, 54, 1896-1902.
31. Lou, Y.; McDonald, P. C.; Oloumi, A.; Chia, S. K.; Ostlund, C.; Ahmadi, A.; Kyle, A.; Auf dem Keller, U.; Leung, S.; Huntsman, D. G.; Clarke, B.; Sutherland, B. W.; Waterhouse, D.; Bally, M. B.; Roskelley, C. D.; Overall, C. M.; Minchinton, A.; Pacchiano, F.; Carta, F.; Scozzafava, A.; Touisni, N.; Winum, J. Y.; Supuran, C. T.; Dedhar, S. Targeting tumor hypoxia: Suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011, 71, 3364-3376.
32. Penverne, C.; Ferrières, V. Synthesis of 4-methylumbellifer-7-yl- α-D-mannopyranoside: An introduction to modern glycosylation reactions. J. Chem. Educ. 2002, 79, 1353-1361.
33. (a) Wilkinson, B. L.; Bornaghi, L. F.; Houston, T. A.; Innocente, A.; Supuran, C. T.; Poulsen, S.-A. A novel class of carbonic anhydrase inhibitors: Glycoconjugate benzene sulfonamides prepared by "click-tailing". J. Med. Chem. 2006, 49, 6539-6548.
34. (b) Wilkinson, B. L.; Bornaghi, L. F.; Houston, T. A.; Innocenti, A.; Vullo, D.; Supuran, C. T.; Poulsen, S.-A. Carbonic anhydrase inhibitors: Inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides. J. Med. Chem. 2007, 50, 1651-1657.
35. (c) Wilkinson, B. L.; Bornaghi, L. F.; Houston, T. A.; Innocenti, A.; Vullo, D.; Supuran, C. T.; Poulsen, S.-A. Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg. Med. Chem. Lett. 2007, 17, 987-992.
36. (a) Winum, J.-Y.; Casini, A.; Mincione, F.; Starnotti, M.; Montero, J.-L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: N-(p-Sulfamoylphenyl)-α-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg. Med. Chem. Lett. 2004, 14, 225-229.
37. (b) Wilkinson, B. L.; Innocenti, A.; Vullo, D.; Supuran, C. T.; Poulsen, S.-A. Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J. Med. Chem. 2008, 51, 1945-1953.
38. (c) Lopez, M.; Bornaghi, L. F.; Innocenti, A.; Vullo, D.; Charman, S. A.; Supuran, C. T.; Poulsen, S.-A. Sulfonamide linked neoglycoconjugates: A new class of inhibitors for cancer-associated carbonic anhydrases. J. Med. Chem. 2010, 53, 2913-2926.
39. (d) Singer, M.; Lopez, M.; Bornaghi, L. F.; Innocenti, A.; Vullo, D.; Supuran, C. T.; Poulsen, S.-A. Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties. Bioorg. Med. Chem. Lett. 2009, 19, 2273-2276.
40. Khalifah, R. G. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J. Biol. Chem. 1971, 246, 2561-2573.
41. Lou, Y.; Preobrazhenska, O.; auf dem Keller, U.; Sutcliffe, M.; Barclay, L.; McDonald, P. C.; Roskelley, C.; Overall, C. M.; Dedhar, S. Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis. Dev. Dyn. 2008, 237, 2755-2768.
42. Chen, C. L.; Chu, J. S.; Su, W. C.; Huang, S. C.; Lee, W. Y. Hypoxia and metabolic phenotypes during breast carcinogenesis: Expression of HIF-1α, GLUT1, and CAIX. Virchows Arch. 2010, 457, 53-61.
43. Kristiansen, G.; Rose, M.; Geisler, C.; Fritzsche, F. R.; Gerhardt, J.; Luke, C.; Ladhoff, A. M.; Knuchel, R.; Dietel, M.; Moch, H.; Varga, Z.; Theurillat, J. P.; Gorr, T. A.; Dahl, E. Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype. Br. J. Cancer 2010, 102, 1736-1745.
44. (a) Chia, S. K.; Wykoff, C. C.; Watson, P. H.; Han, C.; Leek, R. D.; Pastorek, J.; et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 2001, 19, 3660-3668.
45. (b) Wykoff, C. C.; Beasley, N. J.; Watson, P. H.; Turner, K. J.; Pastorek, J.; Sibtain, A.; Wilson, G. D.; Turley, H.; Talks, K. L.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J.; Harris, A. L. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60, 7075-7083.
46. (c) Bartosova, M.; Parkkila, S.; Pohlodek, K.; Karttunen, T. J.; Galbavy, S.; Mucha, V.; Harris, A. L.; Pastorek, J.; Pastorekova, S. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J. Pathol. 2002, 197, 1-8.
47. Hussain, S. A.; Ganesan, R.; Reynolds, G.; Gross, L.; Stevens, A.; Pastorek, J.; Murray, P. G.; Perunovic, B.; Anwar, M. S.; Billingham, L.; James, N. D.; Spooner, D.; Poole, C. J.; Rea, D. W.; Palmer, D. H. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br. J. Cancer 2007, 96, 104-109.